[{"path":"msdllcpapers.github.io/oncoPoS/articles/oncoPoS.html","id":"overview","dir":"Articles","previous_headings":"","what":"Overview","title":"Introduction to oncoPoS","text":"oncoPoS performs Probability Success (PoS) calculations phase 3 oncology study using Bayesian Hierarchical model. prior model based data observed earlier study, design features phase 3 study assessed industry benchmark success. Bayesian framework used oncoPoS relies work (Hampson et al. 2022). See PoS Bayesian Framework vignette details. main functions oncoPoS run_stan gen_pos, generate PoS estimate standard error (SE) planned analysis running rstan. Note SE PoS estimate generated without considering observed treatment effect earlier study,","code":""},{"path":"msdllcpapers.github.io/oncoPoS/articles/oncoPoS.html","id":"pos-estimate-example","dir":"Articles","previous_headings":"","what":"PoS estimate example","title":"Introduction to oncoPoS","text":"Let‚Äôs assume designed phase 3 randomized oncology trial certain disease setting progression-free survival (PFS) primary endpoint. design features study follows: Target hazard ratio (HR): 0.70; Group sequential design two analysis; Target number events analysis: 370, 468; Approximate HR bound analysis: 0.779, 0.8204. overall alpha level 2.5% power 95.5% seen design features general, considered direct design features PoS estimation therefore inputs oncoPoS relevant functions. proceed PoS estimation, industry benchmark required well. ‚Äôll assume , without considering specific design features trial, 50% chance trial successful.","code":""},{"path":"msdllcpapers.github.io/oncoPoS/articles/oncoPoS.html","id":"no-earlier-study-data","dir":"Articles","previous_headings":"PoS estimate example","what":"No earlier study data","title":"Introduction to oncoPoS","text":"specific earlier study linked directly phase 3 objective response rate (ORR) PFS, PoS estimate analysis calculated following:","code":"library(oncoPoS)  gen_pos(   target_hr = 0.7,   J = 2,     nevents3 = c(370, 468),    hr_bound = c(0.779, 0.8204),   omega = 0.5,   seed = 245  ) ## # A tibble: 2 √ó 3 ##       J   pos pos_se ##   <int> <dbl>  <dbl> ## 1     1 0.414 0.0110 ## 2     2 0.492 0.0112"},{"path":"msdllcpapers.github.io/oncoPoS/articles/oncoPoS.html","id":"prior-pfs-data","dir":"Articles","previous_headings":"PoS estimate example","what":"Prior PFS data","title":"Introduction to oncoPoS","text":"Let‚Äôs change scenario assume randomized phase 2 trial observed PFS hazard ratio (HR) 0.53 95% confidence interval (CI) (0.31, 0.91). phase 2 trial led decision continue clinical development compound specific disease setting thus design phase 3 trial. additional information incorporated PoS estimates follows:","code":"gen_pos(   target_hr = 0.7,   J = 2,     nevents3 = c(370, 468),    hr_bound = c(0.779, 0.8204),   omega = 0.5,    use_pfs = TRUE,   est_obs_pfs = 0.53,    low_obs_pfs = 0.31,    upp_obs_pfs = 0.91,   seed = 245  ) ## # A tibble: 2 √ó 3 ##       J   pos  pos_se ##   <int> <dbl>   <dbl> ## 1     1 0.73  0.00993 ## 2     2 0.812 0.00874"},{"path":"msdllcpapers.github.io/oncoPoS/articles/oncoPoS.html","id":"prior-orr-data","dir":"Articles","previous_headings":"PoS estimate example","what":"Prior ORR data","title":"Introduction to oncoPoS","text":"earlier study didn‚Äôt reliable PFS estimate ORR available, can used PoS estimation well. assume , based earlier study 33 60 18 63 participants experimental control arms responses respectively. case, ORR data used, coefficients linear relationship log treatment effect ORR PFS must specified:","code":"gen_pos(   target_hr = 0.7,   J = 2,     nevents3 = c(370, 468),    hr_bound = c(0.779, 0.8204),   omega = 0.5,   use_orr = TRUE,   n_resp_trt2 = 33,   n_trt2 = 60,   n_resp_ctrl2 = 18,    n_ctrl2 = 63,   m_0 = -0.20,   m_1 = 2.2,   nu_0 = 0.0541,   nu_1 = 0.2145,   lm_sd = 5.1158,   seed = 245  ) ## # A tibble: 2 √ó 3 ##       J   pos pos_se ##   <int> <dbl>  <dbl> ## 1     1 0.572 0.0111 ## 2     2 0.656 0.0106"},{"path":"msdllcpapers.github.io/oncoPoS/articles/pos_bayes_framework.html","id":"introduction","dir":"Articles","previous_headings":"","what":"Introduction","title":"PoS Bayesian Framework for Pivotal Oncology Trials","text":"describe Bayesian framework used estimate phase 3 efficacy probability success (PoS) based work Hampson et al. (2022). framework consists study population level models described following sections. Let PP progression-free survival (PFS), assume log hazard ratio (HR) PFS phase III study Œ∏P3\\theta_{P3}. subscript 3 denotes phase study (.e., phase III). addition, assume data either endpoint PP different endpoint DD observed earlier phase /II phase II study preceded pivotal trial (Œ∏P2\\theta_{P2} Œ∏D2\\theta_{D2} respectively).","code":""},{"path":"msdllcpapers.github.io/oncoPoS/articles/pos_bayes_framework.html","id":"general-study-level-model","dir":"Articles","previous_headings":"","what":"General study level model","title":"PoS Bayesian Framework for Pivotal Oncology Trials","text":"study level model observed logHR PFS earlier study (phase /II, phase II), Œ∏ÃÇP2\\hat{\\theta}_{P2}, assumed following form: Œ∏ÃÇP2‚àºNormal(Œ∏P2,‚ÑêP2‚àí1),\\begin{align} \\hat{\\theta}_{P2} \\sim Normal(\\theta_{P2}, \\mathcal{}^{-1}_{P2}) \\label{eq:ph2_est}, \\end{align} Œ∏P2\\theta_{P2} represents mean treatment effect PP earlier study ‚ÑêP2\\mathcal{}_{P2} Fisher information Œ∏P2\\theta_{P2}. Using Bayesian framework, prior Œ∏P2\\theta_{P2} : Œ∏P2‚àºNormal(ŒºP,œÑP22),\\theta_{P2} \\sim Normal (\\mu_P, \\tau_{P2}^2), ŒºP\\mu_P population level parameter treatment effect PP. œÑP2\\tau_{P2} characterizes degree heterogeneity treatment effect PP across different earlier studies, assumed follow half-Normal distribution: œÑP2‚àºHN(z22)\\tau_{P2} \\sim HN(z^2_2). Similar , phase III study level model treatment effect endpoint PP, Œ∏P3\\theta_{P3} following distribution: Œ∏P3‚àºNormal(ŒºP,œÑP32)\\begin{align} \\theta_{P3} \\sim Normal (\\mu_P, \\tau_{P3}^2)\\label{eq:p3} \\end{align} population level parameter ŒºP\\mu_P shared across phases clinical development. œÑP3\\tau_{P3} assumed follow half-Normal distribution: œÑP3‚àºHN(z32)\\tau_{P3} \\sim HN(z^2_3). choice œÑP2,œÑP3\\tau_{P2},\\ \\tau_{P3} follow Supplementary Materials E Hampson et al. (2022).","code":""},{"path":"msdllcpapers.github.io/oncoPoS/articles/pos_bayes_framework.html","id":"population-level-model","dir":"Articles","previous_headings":"","what":"Population level model","title":"PoS Bayesian Framework for Pivotal Oncology Trials","text":"population level treatment effect, ŒºP\\mu_P, assumed come mixture prior: ŒºP‚àºœâNormal(Œ¥P,œÉP12)+(1‚àíœâ)Normal(0,œÉP22),\\begin{align} \\mu_{P} \\sim \\omega Normal (\\delta_{P}, \\sigma_{P1}^2) + (1-\\omega) Normal(0, \\sigma_{P2}^2) , \\end{align} following components: ww probability ŒºP\\mu_P comes enthusiastic prior component. value ww determined industry benchmark. Normal(Œ¥P,œÉP12)Normal(\\delta_P, \\sigma^2_{P1}) enthusiastic component, .e., distribution centered target treatment effect Œ¥P\\delta_P (.e., alternative hypothesis). œÉP12\\sigma^2_{P1} set solution : P(ŒºP‚â•0|œâ=1)=Œ≥P(\\mu_P \\ge 0 | \\omega = 1)=\\gamma, consistent interpretation enthusiastic (‚Äúalternative‚Äù) component, ‚áîœÉP1=Œ¥PŒ¶‚àí1(Œ≥)\\Leftrightarrow \\sigma_{P1} = \\frac{\\delta_P}{\\Phi^{-1}(\\gamma)}. Normal(0,œÉP22)Normal(0, \\sigma^2_{P2}) skeptical component, .e., distribution centered null hypothesis. œÉP22\\sigma^2_{P2} set solution : P(ŒºP‚â§Œ¥P|œâ=0)=Œ≥P(\\mu_P \\le \\delta_P | \\omega = 0)=\\gamma, consistent interpretation skeptical (‚Äúnull‚Äù) component, ‚áîœÉP2=Œ¥PŒ¶‚àí1(Œ≥)\\Leftrightarrow \\sigma_{P2} = \\frac{\\delta_P}{\\Phi^{-1}(\\gamma)}. PP denotes logHR PFS, Œ≥\\gamma probability population level treatment effect equal worse null (.e., logHR ‚â•0\\ge 0) benchmarking data indicate optimistic expectation treatment effect; probability population level treatment effect equal better target effect phase III (.e., logHR ‚â§Œ¥P\\le \\delta_P) benchmarking data indicate pessimistic expectation treatment effect. Œ≥\\gamma set small number probability either lack treatment effect enthusiastic prior substaintial treatment effect pessimistic prior small.","code":""},{"path":"msdllcpapers.github.io/oncoPoS/articles/pos_bayes_framework.html","id":"phase-iii-efficacy-pos-prediction","dir":"Articles","previous_headings":"","what":"Phase III efficacy PoS prediction","title":"PoS Bayesian Framework for Pivotal Oncology Trials","text":"fitting models outlined , can generate phase III efficacy PoS prediction based distribution Œ∏P3\\theta_{P3}. Let JJ denotes number analyses considered group sequential design future phase III study. instance, J=2J = 2, means study one interim analysis (IA) one final analysis (FA). distribution observed log HR endpoint PP jj-th analysis, Œ∏ÃÇP3j,j=1,...,J\\hat{\\theta}_{P3j}, j = 1, ..., J follows: ùõâÃÇP3‚àºNormal(Œ∏P3ùüèJ,ùö∫J√óJ),\\begin{align} \\hat{\\boldsymbol{\\theta}}_{P3} \\sim Normal ({\\theta}_{P3}\\mathbf{1}_{J}, \\mathbf{\\Sigma}_{J \\times J})\\label{eq:thetahat_samp}, \\end{align} Œ∏P3\\theta_{P3} underlying true log hazard ratio JJ analyses. ùö∫\\mathbf{\\Sigma} covariance matrix encodes Fisher‚Äôs information Œ∏ÃÇP3j\\hat{\\theta}_{P3j}: ùö∫ij=œÉunit2nj,‚â§j,\\begin{align} \\mathbf{\\Sigma}_{ij} = \\frac{\\sigma_{unit}^2}{n_j}, ~~ \\text{} \\leq j\\label{eq:sigma}, \\end{align} njn_j target number events jj-th analysis œÉunit2=1p0(1‚àíp0)\\sigma_{unit}^2 = \\frac{1}{p_0(1-p_0)} p0p_0 planned proportion patients control group. predicted treatment effect ùõâÃÇP3(l)\\hat{\\boldsymbol{\\theta}}_{P3}^{(l)} generated LL times (l=1,‚Ä¶,Ll = 1, \\dots, L) based Bayesian hierarchical model success jj-th analysis determined Frequentest efficacy boundary, zP3jz_{P3j}. Thus, probability stopping phase III trial efficacy first IA estimated : PoSÃÇ31=1L‚àël=1LI(Œ∏ÃÇP31(l)<zP31), \\hat{PoS}_{31} = \\frac{1}{L} \\sum_{l=1}^L (\\hat{\\theta}_{P31}^{(l)} < z_{P31}),  probability stopping phase III trial efficacy jthj^{th} analysis estimated : PoSÃÇ3j=1L‚àël=1LI(Œ∏ÃÇP3j(l)<zP3j,Œ∏ÃÇP3i(l)‚â•zP3i,=1,‚Ä¶,j‚àí1). \\hat{PoS}_{3j} = \\frac{1}{L} \\sum_{l=1}^L (\\hat{\\theta}_{P3j}^{(l)} < z_{P3j}, \\hat{\\theta}_{P3i}^{(l)} \\geq z_{P3i}, = 1, \\dots, j-1).  Finally, overall PoS : PoSÃÇ3=‚àëj=1JPoSÃÇ3j\\hat{PoS}_{3} = \\sum_{j=1}^J \\hat{PoS}_{3j}.","code":""},{"path":"msdllcpapers.github.io/oncoPoS/articles/pos_bayes_framework.html","id":"study-level-model-when-phase-iii-primary-endpoint-is-not-available-from-earlier-studyies","dir":"Articles","previous_headings":"","what":"Study level model when phase III primary endpoint is not available from earlier study(ies)","title":"PoS Bayesian Framework for Pivotal Oncology Trials","text":"early study didn‚Äôt reliable PFS estimate, ORR available randomized controlled phase II study, can used PoS estimation instead. Let Œ∏ORR,2\\theta_{ORR,2} represents log odds ratio () treatment effect ORR, observed treatment effect, Œ∏ÃÇORR,2\\hat{\\theta}_{ORR, 2}, following distribution: Œ∏ÃÇORR,2‚àºNormal(Œ∏ORR,2,‚ÑêORR,2‚àí1),\\begin{align} \\hat{\\theta}_{ORR, 2} \\sim Normal(\\theta_{ORR, 2}, \\mathcal{}_{ORR, 2}^{-1}), \\end{align} ‚ÑêORR,2\\mathcal{}_{ORR, 2} Fisher information associated Œ∏ÃÇORR,2\\hat{\\theta}_{ORR, 2}. , let Œ∏PFS,2\\theta_{PFS, 2} treatment effect PFS Phase II. Motivated results Blumenthal et al. (2015), assume following linear model PFS ORR treatment effects: Œ∏ORR,2‚àºN(Œ≤0+Œ≤1Œ∏PFS,2,œÉWLS2Npatients),\\begin{align}   \\theta_{ORR,2} \\sim N(\\beta_0 + \\beta_1 \\theta_{PFS,2}, \\frac{\\sigma_{WLS}^2}{N_{patients}}), \\label{eq:ph23_pfs_orr_rel} \\end{align} NpatientsN_{patients} number patients given trial regression parameters assigned following priors: Œ≤0‚àºNormal(m0,ŒΩ0)Œ≤1‚àºNormal(m1,ŒΩ1).\\begin{align*} \\beta_0 \\sim {Normal}(m_0, \\nu_0) \\\\ \\beta_1 \\sim {Normal}(m_1, \\nu_1).  \\end{align*} values m0,m1m_0, m_1, ŒΩ0,ŒΩ1\\nu_0, \\nu_1 œÉWLS2\\sigma_{WLS}^2 determined historical data, provided meta-analysis Blumenthal et al. (2015). Specifically, (m0,m1)(m_0, m_1) point estimates intercept slope weighted liner simple (WLS) linear regression model log(HR PFS) log(ORR), (ŒΩ0,ŒΩ1)(\\nu_0, \\nu_1) respective SEs, œÉWLS2\\sigma_{WLS}^2 estimated based WLS regression residual variance. Based approximated correlation Œ∏ORR,2\\theta_{ORR, 2} Œ∏PFS,2\\theta_{PFS, 2}, distribution Œ∏PFS,2\\theta_{PFS, 2} can obtained , therefore, predicated efficacy PoS can estimated using models outlined .","code":""},{"path":"msdllcpapers.github.io/oncoPoS/articles/testing-plan.html","id":"summary-of-testing-plan","dir":"Articles","previous_headings":"","what":"Summary of testing plan","title":"Function Validation Plan","text":"Validation details located tests/testthat/ folder.","code":""},{"path":"msdllcpapers.github.io/oncoPoS/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"Yulia Sidi. Author, maintainer. Xiang Peng. Author. Alex Ziyu Jiang. Author. BARDS, MSD. Copyright holder.","code":""},{"path":"msdllcpapers.github.io/oncoPoS/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Sidi Y, Peng X, Ziyu Jiang (2026). oncoPoS: Probability Success (PoS) Calculation Oncology Pivotal Studies. R package version 0.1.0, https://github.com/MSDLLCPapers/onsoPoS.","code":"@Manual{,   title = {oncoPoS: Probability of Success (PoS) Calculation for Oncology Pivotal Studies},   author = {Yulia Sidi and Xiang Peng and Alex {Ziyu Jiang}},   year = {2026},   note = {R package version 0.1.0},   url = {https://github.com/MSDLLCPapers/onsoPoS}, }"},{"path":[]},{"path":"msdllcpapers.github.io/oncoPoS/index.html","id":"overview","dir":"","previous_headings":"","what":"Overview","title":"Probability of Success (PoS) Calculation for Oncology Pivotal Studies","text":"oncoPoS performs Probability Success (PoS) calculations phase 3 oncology study using Bayesian Hierarchical model. prior model based data observed earlier study, design features phase 3 study assessed industry benchmark success.","code":""},{"path":"msdllcpapers.github.io/oncoPoS/index.html","id":"installation","dir":"","previous_headings":"","what":"Installation","title":"Probability of Success (PoS) Calculation for Oncology Pivotal Studies","text":"can install development version oncoPoS GitHub :","code":"if (!requireNamespace(\"remotes\")) {   install.packages(\"remotes\") } remotes::install_github(\"MSDLLCPapers/oncoPoS\")"},{"path":"msdllcpapers.github.io/oncoPoS/index.html","id":"example","dir":"","previous_headings":"","what":"Example","title":"Probability of Success (PoS) Calculation for Oncology Pivotal Studies","text":"simple example assumes following information available oncology phase 3 trial PoS calculation: Design features phase 3 trial: Progression-free survival (PFS) primary endpoint target hazard ratio (HR) 0.7; Two analyses using group sequential approach planned; number target events analysis 370 468; approximate HR bound analysis 0.7790 0.8204; randomization ratio 2:1. phase 3 trial planned following promising results earlier phase 2 study, reported PFS HR (95% CI) 0.53 (0.31, 0.91). industry benchmark success 0.57 type phase 3 trial. information synthesized oncoPoS::gen_pos() using Bayesian Hierarchical model generate PoS estimate:","code":"gen_pos(   target_hr =  0.70,   J = 2,   nevents3 = c(370, 468),   hr_bound = c(0.7790, 0.8204),   est_obs_pfs = 0.53,   low_obs_pfs = 0.31,   upp_obs_pfs = 0.91,   omega = 0.57,   seed = 574,   ratio = 2,   use_pfs = TRUE,   nchains = 4,   niter = 1000 )"},{"path":"msdllcpapers.github.io/oncoPoS/reference/gen_pos.html","id":null,"dir":"Reference","previous_headings":"","what":"PoS estimation ‚Äî gen_pos","title":"PoS estimation ‚Äî gen_pos","text":"PoS estimation","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/gen_pos.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"PoS estimation ‚Äî gen_pos","text":"","code":"gen_pos(   target_hr,   J,   nevents3,   hr_bound,   omega,   est_obs_pfs,   low_obs_pfs,   upp_obs_pfs,   obs_pfs_conf_level = 0.95,   thres = 0.01,   n_trt2,   n_ctrl2,   n_resp_trt2,   n_resp_ctrl2,   use_orr = FALSE,   use_pfs = FALSE,   het_degree_p2 = \"small\",   het_degree_p3 = \"very small\",   ratio = 1,   m_0 = NA,   m_1 = NA,   nu_0 = NA,   nu_1 = NA,   lm_sd = NA,   niter = 1000,   nchains = 4,   ncores = 4,   seed,   plots_out = FALSE,   ... )"},{"path":"msdllcpapers.github.io/oncoPoS/reference/gen_pos.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"PoS estimation ‚Äî gen_pos","text":"target_hr target hazard ration phase 3 study (.e., alternative hypothesis) J number planned analyses phase 3 study nevents3 numeric vector target number events phase 3 study hr_bound numeric vector hazard ratio bounds analyses phase 3 study omega probability treatment effect comes enthusiastic prior component, .e., initial benchmarking probability study success est_obs_pfs estimated PFS hazard ratio based prior/earlier study low_obs_pfs lower bound estimated PFS hazard ratio based prior/earlier study upp_obs_pfs upper bound estimated PFS hazard ratio based prior/earlier study obs_pfs_conf_level confidence level estimated PFS hazard ratio bounds, Default: 0.95 thres probability either lack treatment effect enthusiastic prior substantial treatment effect pessimistic prior. set small value, close 0, Default: 0.01 n_trt2 sample size treatment arm prior/earlier study n_ctrl2 sample size control arm prior/earlier study n_resp_trt2 number responses treatment arm prior/earlier study n_resp_ctrl2 number responses control arm prior/earlier study use_orr whether response data prior/earlier study used, Default: FALSE use_pfs whether PFS data prior/earlier study used, Default: FALSE het_degree_p2 indicates degree heterogeneity study level parameter prior/earlier study must one \"large\", \"substantial\", \"moderate\", \"small\", \"small\", Default: 'small'. het_degree_p3 indicates degree heterogeneity study level parameter phase 3 study must one \"large\", \"substantial\", \"moderate\", \"small\", \"small\", Default: 'small' ratio randomization ratio experimental arm compared control m_0 intercept linear regression log treatment effect PFS log treatment effect response. value expected use_orr = TRUE use_pfs = TRUE, Default: NA m_1 slope linear regression log treatment effect PFS log treatment effect response. value expected use_orr = TRUE use_pfs = TRUE, Default: NA nu_0 standard error m_0. value expected use_orr = TRUE use_pfs = TRUE, Default: NA nu_1 standard error m_1. value expected use_orr = TRUE use_pfs = TRUE, Default: NA lm_sd linear regression residual variance log treatment effect PFS log treatment effect response. value expected use_orr = TRUE use_pfs = TRUE, Default: NA niter number iterations used stan run, Default: 1000 nchains number chains used stan run, Default: 4 ncores number cores used stan run, Default: 4 seed seed used stan run plots_out whether plots MCMC chains autocorrelation printed, Default: FALSE ... params pass stan run","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/gen_pos.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"PoS estimation ‚Äî gen_pos","text":"tibble PoS estimates corresponding standard errors analysis. plots_out turned , MCMC chains mixing autocorrelation plots provided well.","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/gen_pos.html","id":"specification","dir":"Reference","previous_headings":"","what":"Specification","title":"PoS estimation ‚Äî gen_pos","text":"contents section shown PDF user manual .","code":""},{"path":[]},{"path":"msdllcpapers.github.io/oncoPoS/reference/gen_pos.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"PoS estimation ‚Äî gen_pos","text":"","code":"# use PFS data from a prior study    gen_pos(     target_hr = 0.7,      J = 2,       nevents3 = c(370, 468),      hr_bound = c(0.779, 0.8204),      omega = 0.5,      est_obs_pfs = 0.88,      low_obs_pfs = 0.74,      upp_obs_pfs = 1.05,      use_pfs = TRUE,      seed = 325,     ncores = 1,     nchains = 1)  #>  #> SAMPLING FOR MODEL 'anon_model' NOW (CHAIN 1). #> Chain 1:  #> Chain 1: Gradient evaluation took 6e-06 seconds #> Chain 1: 1000 transitions using 10 leapfrog steps per transition would take 0.06 seconds. #> Chain 1: Adjust your expectations accordingly! #> Chain 1:  #> Chain 1:  #> Chain 1: Iteration:   1 / 1000 [  0%]  (Warmup) #> Chain 1: Iteration: 100 / 1000 [ 10%]  (Warmup) #> Chain 1: Iteration: 200 / 1000 [ 20%]  (Warmup) #> Chain 1: Iteration: 300 / 1000 [ 30%]  (Warmup) #> Chain 1: Iteration: 400 / 1000 [ 40%]  (Warmup) #> Chain 1: Iteration: 500 / 1000 [ 50%]  (Warmup) #> Chain 1: Iteration: 501 / 1000 [ 50%]  (Sampling) #> Chain 1: Iteration: 600 / 1000 [ 60%]  (Sampling) #> Chain 1: Iteration: 700 / 1000 [ 70%]  (Sampling) #> Chain 1: Iteration: 800 / 1000 [ 80%]  (Sampling) #> Chain 1: Iteration: 900 / 1000 [ 90%]  (Sampling) #> Chain 1: Iteration: 1000 / 1000 [100%]  (Sampling) #> Chain 1:  #> Chain 1:  Elapsed Time: 0.017 seconds (Warm-up) #> Chain 1:                0.009 seconds (Sampling) #> Chain 1:                0.026 seconds (Total) #> Chain 1:  #> # A tibble: 2 √ó 3 #>       J   pos pos_se #>   <int> <dbl>  <dbl> #> 1     1 0.202 0.0180 #> 2     2 0.322 0.0209"},{"path":"msdllcpapers.github.io/oncoPoS/reference/gen_sigma.html","id":null,"dir":"Reference","previous_headings":"","what":"Generate covariance matrix for observed treatment effect in phase 3 ‚Äî gen_sigma","title":"Generate covariance matrix for observed treatment effect in phase 3 ‚Äî gen_sigma","text":"Generates covariance matrix observed treatment effect, .e., log hazard ratio phase 3 trial","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/gen_sigma.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generate covariance matrix for observed treatment effect in phase 3 ‚Äî gen_sigma","text":"","code":"gen_sigma(n_events, ratio = 1)"},{"path":"msdllcpapers.github.io/oncoPoS/reference/gen_sigma.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generate covariance matrix for observed treatment effect in phase 3 ‚Äî gen_sigma","text":"n_events numeric vector target number events phase 3 ratio randomization ratio experimental arm compared control","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/gen_sigma.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Generate covariance matrix for observed treatment effect in phase 3 ‚Äî gen_sigma","text":"sigma_unit covariance matrix used PoS prediction","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/gen_sigma.html","id":"specification","dir":"Reference","previous_headings":"","what":"Specification","title":"Generate covariance matrix for observed treatment effect in phase 3 ‚Äî gen_sigma","text":"contents section shown PDF user manual .","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/gen_sigma.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Generate covariance matrix for observed treatment effect in phase 3 ‚Äî gen_sigma","text":"","code":"if (FALSE) gen_sigma(c(100, 150), ratio = 1) # \\dontrun{}"},{"path":"msdllcpapers.github.io/oncoPoS/reference/get_denominator.html","id":null,"dir":"Reference","previous_headings":"","what":"Transform degree of heterogeneity to denominator ‚Äî get_denominator","title":"Transform degree of heterogeneity to denominator ‚Äî get_denominator","text":"Helper function: transform degree heterogeneity denominator","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/get_denominator.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Transform degree of heterogeneity to denominator ‚Äî get_denominator","text":"","code":"get_denominator(input)"},{"path":"msdllcpapers.github.io/oncoPoS/reference/get_denominator.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Transform degree of heterogeneity to denominator ‚Äî get_denominator","text":"input indicates degree heterogeneity study level parameter, must one \"large\", \"substantial\", \"moderate\", \"small\", \"small\"","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/get_denominator.html","id":"specification","dir":"Reference","previous_headings":"","what":"Specification","title":"Transform degree of heterogeneity to denominator ‚Äî get_denominator","text":"contents section shown PDF user manual .","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/resp2oddsratio.html","id":null,"dir":"Reference","previous_headings":"","what":"Estimate log odds ratio given response ‚Äî resp2oddsratio","title":"Estimate log odds ratio given response ‚Äî resp2oddsratio","text":"Estimates log odds ratio treatment vs control based number responses samples size arm","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/resp2oddsratio.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Estimate log odds ratio given response ‚Äî resp2oddsratio","text":"","code":"resp2oddsratio(n_resp_trt, n_resp_ctrl, n_trt, n_ctrl)"},{"path":"msdllcpapers.github.io/oncoPoS/reference/resp2oddsratio.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Estimate log odds ratio given response ‚Äî resp2oddsratio","text":"n_resp_trt number responses treatment arm n_resp_ctrl number responses control arm n_trt sample size treatment arm n_ctrl sample size control arm","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/resp2oddsratio.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Estimate log odds ratio given response ‚Äî resp2oddsratio","text":"log odds ratio point estimate corresponding standard error","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/resp2oddsratio.html","id":"specification","dir":"Reference","previous_headings":"","what":"Specification","title":"Estimate log odds ratio given response ‚Äî resp2oddsratio","text":"contents section shown PDF user manual .","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/resp2oddsratio.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Estimate log odds ratio given response ‚Äî resp2oddsratio","text":"","code":"resp2oddsratio(n_resp_trt = 20, n_resp_ctrl = 10, n_trt = 40, n_ctrl = 45) #> $est #> [1] -1.252763 #>  #> $se #> [1] 0.4780914 #>"},{"path":"msdllcpapers.github.io/oncoPoS/reference/run_stan.html","id":null,"dir":"Reference","previous_headings":"","what":"Run stan to generate a PoS prediction ‚Äî run_stan","title":"Run stan to generate a PoS prediction ‚Äî run_stan","text":"wrapper function run stan order generate PoS prediction","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/run_stan.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Run stan to generate a PoS prediction ‚Äî run_stan","text":"","code":"run_stan(   target_hr,   J,   nevents3,   hr_bound,   omega,   est_obs_pfs,   low_obs_pfs,   upp_obs_pfs,   obs_pfs_conf_level = 0.95,   thres = 0.01,   n_trt2,   n_ctrl2,   n_resp_trt2,   n_resp_ctrl2,   use_orr = FALSE,   use_pfs = FALSE,   het_degree_p2 = \"small\",   het_degree_p3 = \"very small\",   ratio = 1,   m_0 = NA,   m_1 = NA,   nu_0 = NA,   nu_1 = NA,   lm_sd = NA,   niter = 1000,   nchains = 4,   ncores = 4,   seed,   ... )"},{"path":"msdllcpapers.github.io/oncoPoS/reference/run_stan.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Run stan to generate a PoS prediction ‚Äî run_stan","text":"target_hr target hazard ration phase 3 study (.e., alternative hypothesis) J number planned analyses phase 3 study nevents3 numeric vector target number events phase 3 study hr_bound numeric vector hazard ratio bounds analyses phase 3 study omega probability treatment effect comes enthusiastic prior component, .e., initial benchmarking probability study success est_obs_pfs estimated PFS hazard ratio based prior/earlier study low_obs_pfs lower bound estimated PFS hazard ratio based prior/earlier study upp_obs_pfs upper bound estimated PFS hazard ratio based prior/earlier study obs_pfs_conf_level confidence level estimated PFS hazard ratio bounds, Default: 0.95 thres probability either lack treatment effect enthusiastic prior substantial treatment effect pessimistic prior. set small value, close 0, Default: 0.01 n_trt2 sample size treatment arm prior/earlier study n_ctrl2 sample size control arm prior/earlier study n_resp_trt2 number responses treatment arm prior/earlier study n_resp_ctrl2 number responses control arm prior/earlier study use_orr whether response data prior/earlier study used, Default: FALSE use_pfs whether PFS data prior/earlier study used, Default: FALSE het_degree_p2 indicates degree heterogeneity study level parameter prior/earlier study must one \"large\", \"substantial\", \"moderate\", \"small\", \"small\", Default: 'small'. het_degree_p3 indicates degree heterogeneity study level parameter phase 3 study must one \"large\", \"substantial\", \"moderate\", \"small\", \"small\", Default: 'small' ratio randomization ratio experimental arm compared control m_0 intercept linear regression log treatment effect PFS log treatment effect response. value expected use_orr = TRUE use_pfs = TRUE, Default: NA m_1 slope linear regression log treatment effect PFS log treatment effect response. value expected use_orr = TRUE use_pfs = TRUE, Default: NA nu_0 standard error m_0. value expected use_orr = TRUE use_pfs = TRUE, Default: NA nu_1 standard error m_1. value expected use_orr = TRUE use_pfs = TRUE, Default: NA lm_sd linear regression residual variance log treatment effect PFS log treatment effect response. value expected use_orr = TRUE use_pfs = TRUE, Default: NA niter number iterations used stan run, Default: 1000 nchains number chains used stan run, Default: 4 ncores number cores used stan run, Default: 4 seed seed used stan run ... params pass stan run","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/run_stan.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Run stan to generate a PoS prediction ‚Äî run_stan","text":"list includes generated stan object, list data supplied rstan::stan(), name stan file run","code":""},{"path":"msdllcpapers.github.io/oncoPoS/reference/run_stan.html","id":"specification","dir":"Reference","previous_headings":"","what":"Specification","title":"Run stan to generate a PoS prediction ‚Äî run_stan","text":"contents section shown PDF user manual .","code":""},{"path":[]},{"path":"msdllcpapers.github.io/oncoPoS/reference/run_stan.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Run stan to generate a PoS prediction ‚Äî run_stan","text":"","code":"# use PFS data from a prior study   run_stan(     target_hr = 0.7,      J = 2,      nevents3 = c(370, 468),      hr_bound = c(0.779, 0.8204),     omega = 0.5,     est_obs_pfs = 0.88,     low_obs_pfs = 0.74,     upp_obs_pfs = 1.05,     use_pfs = TRUE,     seed = 325,     ncores = 1,     nchains = 1) #>  #> SAMPLING FOR MODEL 'anon_model' NOW (CHAIN 1). #> Chain 1:  #> Chain 1: Gradient evaluation took 5e-06 seconds #> Chain 1: 1000 transitions using 10 leapfrog steps per transition would take 0.05 seconds. #> Chain 1: Adjust your expectations accordingly! #> Chain 1:  #> Chain 1:  #> Chain 1: Iteration:   1 / 1000 [  0%]  (Warmup) #> Chain 1: Iteration: 100 / 1000 [ 10%]  (Warmup) #> Chain 1: Iteration: 200 / 1000 [ 20%]  (Warmup) #> Chain 1: Iteration: 300 / 1000 [ 30%]  (Warmup) #> Chain 1: Iteration: 400 / 1000 [ 40%]  (Warmup) #> Chain 1: Iteration: 500 / 1000 [ 50%]  (Warmup) #> Chain 1: Iteration: 501 / 1000 [ 50%]  (Sampling) #> Chain 1: Iteration: 600 / 1000 [ 60%]  (Sampling) #> Chain 1: Iteration: 700 / 1000 [ 70%]  (Sampling) #> Chain 1: Iteration: 800 / 1000 [ 80%]  (Sampling) #> Chain 1: Iteration: 900 / 1000 [ 90%]  (Sampling) #> Chain 1: Iteration: 1000 / 1000 [100%]  (Sampling) #> Chain 1:  #> Chain 1:  Elapsed Time: 0.017 seconds (Warm-up) #> Chain 1:                0.008 seconds (Sampling) #> Chain 1:                0.025 seconds (Total) #> Chain 1:  #> $fit_rstan #> Inference for Stan model: anon_model. #> 1 chains, each with iter=1000; warmup=500; thin=1;  #> post-warmup draws per chain=500, total post-warmup draws=500. #>  #>                  mean se_mean   sd   2.5%   25%   50%   75% 97.5% n_eff Rhat #> mu_P            -0.14    0.01 0.11  -0.35 -0.22 -0.14 -0.06  0.08   200    1 #> tau_P2           0.07    0.00 0.06   0.00  0.03  0.06  0.11  0.19   333    1 #> tau_P3           0.04    0.00 0.03   0.00  0.02  0.03  0.06  0.11   433    1 #> theta_P2_raw     0.13    0.06 1.00  -1.77 -0.52  0.12  0.80  2.02   277    1 #> theta_P3_raw     0.01    0.05 0.99  -1.87 -0.67  0.04  0.71  2.03   351    1 #> theta_P2        -0.13    0.00 0.09  -0.29 -0.19 -0.13 -0.07  0.03   395    1 #> theta_P3        -0.14    0.01 0.12  -0.36 -0.23 -0.13 -0.06  0.09   237    1 #> theta_P3_hat[1] -0.14    0.01 0.14  -0.39 -0.23 -0.13 -0.05  0.15   289    1 #> theta_P3_hat[2] -0.14    0.01 0.13  -0.38 -0.22 -0.14 -0.05  0.13   315    1 #> vec_ones[1]      1.00     NaN 0.00   1.00  1.00  1.00  1.00  1.00   NaN  NaN #> vec_ones[2]      1.00     NaN 0.00   1.00  1.00  1.00  1.00  1.00   NaN  NaN #> lp__            -8.88    0.11 1.60 -12.56 -9.72 -8.66 -7.61 -6.65   224    1 #>  #> Samples were drawn using NUTS(diag_e) at Fri Jan  9 01:11:48 2026. #> For each parameter, n_eff is a crude measure of effective sample size, #> and Rhat is the potential scale reduction factor on split chains (at  #> convergence, Rhat=1). #>  #> $stan_list #> $stan_list$omega #> [1] 0.5 #>  #> $stan_list$delta_P #> [1] -0.3566749 #>  #> $stan_list$sigma_P1 #> [1] 0.1533197 #>  #> $stan_list$sigma_P2 #> [1] 0.1533197 #>  #> $stan_list$tau_sd2 #> [1] 0.09266264 #>  #> $stan_list$tau_sd3 #> [1] 0.04633132 #>  #> $stan_list$J #> [1] 2 #>  #> $stan_list$Sigma #>             [,1]        [,2] #> [1,] 0.005405405 0.004273504 #> [2,] 0.004273504 0.004273504 #>  #> $stan_list$theta_hat #> [1] -0.1278334 #>  #> $stan_list$theta_hat_sd #> [1] 0.08926063 #>  #>  #> $stan_file #> [1] \"phase23_interim_pfs.stan\" #>"},{"path":"msdllcpapers.github.io/oncoPoS/news/index.html","id":"oncopos-010","dir":"Changelog","previous_headings":"","what":"oncoPoS 0.1.0","title":"oncoPoS 0.1.0","text":"Initial version. Added NEWS.md file track changes package.","code":""}]
